Compare DexCom, Inc. (DXCM) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gitlab Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Gitlab Inc trades at $55.07 (market cap $8.92B). The key difference: DexCom, Inc. is far larger — about 3.6× Gitlab Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Gitlab Inc for 62 Days on average.
| DXCM | GTLB | |
|---|---|---|
Market Cap | $31.86B | $8.92B |
Volume | 3,607,070 | 4,716,893 |
Sector | Health | Technology |
52-Week High | $92.34 | $53.56 |
52-Week Low | $54.84 | $19.42 |
Typical Hold Time | 62 Days | 62 Days |
Enterprise Value | $31.32B | $7.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
GitLab (GTLB) is trading at $54.74, up 5.29% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust at 21.3% year-over-year in Q2 2026, though the company continues to operate at a net loss. Recent news highlights strong AI-driven demand and improved sales momentum, with the company raising its full-year guidance.
The outlook is cautiously optimistic with significant revenue growth potential from AI integration, but high valuation multiples and persistent profitability challenges present risks. Analyst consensus leans neutral with a $49.71 price target below current levels, suggesting limited near-term upside despite positive business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
